Source: CureToday articles
Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.
Recent Content
- ASCO 2025 Delivers Insights into Future of Myelofibrosis Care
- S2. Ep 56: Insights from a Pharmacy Times Peer Exchange: How to Talk the Talk
- Day 5: Top Takeaways From ASCO25
- Expert Q&A: Pharmacist-Led Strategies to Improve Cholesterol Management
- Camber Pharmaceuticals Announces Addition of Olmesartan Medoxomil Tablets, USP
- Imdelltra Shows Survival Benefit in Small Cell Lung Cancer
- Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer
- From MGUS to Myeloma: Understanding and Interrupting Disease Progression
- Darolutamide Approved by FDA for Metastatic Castration-Sensitive Prostate Cancer
- June-July 2025: Upcoming NCPA Items for Pharmacy Teams